RankAlpha logo
Back to Rankings

CELC

CelcuityF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
FDA approval for the wild-type indication, confirmed commercial availability, and the submitted mutant sNDA establish a more tangible opportunity than a purely clinical-stage thesis. At June 30, Celcuity reported $754.0 million in cash, equivalents, and short-term investments and expected funding at least into 2029.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -17.0.
What can break
Q2 commercial spending and operating cash use increased; the company's runway expectation depends on future spending and launch execution. Celcuity Q2 release
Momentum
7
Value
41
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $60.00 · Bull $80.00 · Bear $38.00Analysis 2026-10-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-17 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-26

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions

Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $154.69
Why
Momentum7 · Δ7d +0.7
Value41 · Δ7d -0.0
Sentiment45 · Δ7d -17.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Sentiment remains the lead driver in the composite, 7D delta -17.0.

Contradictions & invalidation

  • • Q2 commercial spending and operating cash use increased; the company's runway expectation depends on future spending and launch execution. Celcuity Q2 release
  • • REVTORPYK is commercially available, but verified paid uptake, payer access, and prescribing figures were unavailable in the checked sources. Celcuity launch announcement
  • • Availability does not establish paid demand.

Catalyst clock

2026-10-24

VIKTORIA-1 data at ESMO

Lead driver: Sentiment · See AI snapshot
Momentum
7
8% active weight
Current posture
7d trendFlat
Δ7d
+0.7
Δ21d
-6.3
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
45
45% active weight
Current posture
7d trendSoftening
Δ7d
-17.0
Δ21d
-33.6
Why this grade

Composite grade F. Momentum 7.3 / Value 40.6 / Sentiment 44.8

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-17. Scenario method

B+
Bull case
25%
Probability
Target price
$80.00
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$60.00
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$3.22B
Beta
0.37
Shares Out
48.93M
P/E (TTM) · Derived
-17.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-17.96
Rev YoY
-
EPS YoY
+38.8%
Gross Margin
-
Op Margin
-
Net Debt
-$119.59M
Current Ratio
8.93
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data